Featured Content

Moving Targets: Off-Label Prescribing of Targeted Therapies

By way of the TAPUR study, researchers are attempting to evaluate the activity of targeted therapies when they are used in an off-label setting.

2-Year TKI Consolidation Allowed for TKI Cessation in Select Patients With CML

The majority of patients studied who stopped TKI therapy remained treatment-free at 3 years.

The Patient Behind the EHR: Oncologists Only See Half the Picture

Dr Vorobiof discusses the importance patient factors that can be missed via standard data collection methods for patients with cancer.

Imatinib Determined the Most Cost-Effective Frontline TKI for Chronic Myeloid Leukemia

Cost-effectiveness of TKIs for CML treatment is a complex topic that requires consideration of multiple factors — not just apparent costs to payers.

More Features>>>

Hematologic Cancers Resources

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs